{"doi":"10.1016/j.ijid.2020.08.021","title":"Lassa Fever Induced Hearing Loss: The Neglected Disability of Hemorrhagic Fever","abstract":"OBJECTIVE: Lassa fever (LF) a hemorrhagic fever endemic to Western has an incidence of approximately 500,000 cases per year. Here, we evaluate hearing loss and other sequelae following LF. METHODS: This case-control study enrolled laboratory confirmed LF survivors, non-LF Febrile controls and Matched Community controls with no history of LF or recent hospitalization for a febrile illness. Study participants completed a symptom questionnaire. Pure-tone audiometry was completed by a subset of participants. RESULTS: One hundred forty-seven subjects were enrolled aged from 3-66 years (mean = 23.3). LF survivors were significantly more likely to report balance difficulties (55% vs 20%, p < 0.001), hair loss (32% vs 7%, p < 0.001), difficulty speaking (19% vs 1%, p < 0.001), social isolation (50% vs 0%, p < 0.001), and hearing loss (17% vs 1%, p = 0.002) in comparison to Matched-Community Controls. Similar trends were noted in comparison to Febrile Controls, although these findings were non-significant. Fifty subjects completed audiometry. Audiometry found that LF survivors had significantly more bilateral hearing loss in comparison to Matched-Community Controls (30% vs 4%, p = 0.029). CONCLUSION: This study characterizes the sequelae of LF and highlights the need for increased access to hearing care in West Africa.","journal":"International Journal of Infectious Diseases","year":2020,"id":63823,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":41,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8793,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":337496,"name":"Jeffrey Percak","orcid":"0000-0003-1138-1585","position":1,"is_corresponding":false},{"id":338513,"name":"Sara L. Arguello","orcid":null,"position":2,"is_corresponding":false},{"id":337497,"name":"Alison Bays","orcid":"0000-0002-7193-6303","position":3,"is_corresponding":false},{"id":338514,"name":"Augustine Goba","orcid":null,"position":4,"is_corresponding":false},{"id":338515,"name":"Michael Gbakie","orcid":null,"position":5,"is_corresponding":false},{"id":330630,"name":"Jeffrey G. Shaffer","orcid":"0000-0002-3941-3772","position":6,"is_corresponding":false},{"id":337498,"name":"Susan D. Emmett","orcid":"0000-0003-4257-8161","position":7,"is_corresponding":false},{"id":62205,"name":"John S. Schieffelin","orcid":"0000-0001-6642-5739","position":8,"is_corresponding":false},{"id":337499,"name":"Daniel G. Bausch","orcid":"0000-0002-7209-6983","position":9,"is_corresponding":false},{"id":337495,"name":"Samuel Ficenec","orcid":"0000-0002-4570-201X","position":0,"is_corresponding":true}],"reference_count":66,"raw_metadata":null,"created_at":"2026-07-18T21:11:24.000992Z","pmid":"32795603","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}